The Trendlines Group to Participate at ACCESS CHINA Biotech Forum

By Yafo Life Sciences

January 10th, 2022 (Shanghai) — We are glad to announce that Ofir Hazut, the VP Business Development of The Trendlines Group, together with 4 Trendlines portfolio companies, have been invited to showcase at ACCESS CHINA Biotech Forum during Jan 4th – Jan14th. Ofir will speak about “Israel as a medical tech-hub and introduction to Trendlines”. ACCESS CHINA Biotech Forum is the largest online corporate access event between China and the western biopharma industry.

If you are interested in listening to the live event, please register at https://biotochina.org/register/

About The Trendlines Group

Trendlines is an investment group that invents, invests, and incubates innovation-based medical and agricultural technologies. We invest principally through our incubators: our two Israeli government-franchised incubators, Trendlines Medical and Trendlines Agtech, our Singapore incubators, Trendlines Medical Singapore and AFIC – an agrifood incubator, and our in-house innovation center, Trendlines Labs. As intensely hands-on investors, we are involved in all aspects of our portfolio companies from technology development to business building. Simply stated, we create and develop companies to improve the human condition.

About the speaker

Ofir Hazut has over 15 years of experience and knowledge in life science start-ups and companies. He served as Director of Business Development and CEO in medical devices and agrotech companies. Prior to joining Trendlines, Ofir held the position of Director of Business Development at Evogene and CEO of MEway Pharma, a medical device company. Ofir Hazut advised VCs in investment strategy, deal flow and due diligence processes. Ofir received his B.Sc in Neuroscience and MBA from Bar-Ilan University and M.Sc in Bio-Psychology from Tel-Aviv University.

About ACCESS CHINA

ACCESS CHINA is the most effective deal-making platform for Western pharma and biotech leaders looking to enter or expand in the Chinese market. ACCESS CHINA creates invaluable BD opportunities by directly connecting and meeting with the right partners for development, licensing or commercial collaborations. View more information at https://biotochina.org/access-china-forum/

More information